Valganciclovir hydrochloride is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of cytomegalovirus retinitis (CMV retinitis) in adults with AIDS. Valganciclovir hydrochloride is also FDA-approved for the prevention of CMV disease in recipients of organ transplants who are at risk for CMV diseases. CMV diseases, including CMV retinitis, can be opportunistic infections of HIV. It is grouped under the following drug class(es): DNA polymerase inhibitors and Nucleosides. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Valcyte and Valcyt. Its PubChem CID is 135413534.
Valganciclovir hydrochloride
| CAS No | 175865-59-5 |
|---|---|
| Molecular Formula | C14H23ClN6O5 |
| Molecular Weight | 390.82 g/mol |
| Synonyms | [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
S. Food and Drug Administration (FDA) for the treatment of cytomegalovirus retinitis (CMV retinitis) in adults with AIDS. Valganciclovir hydrochloride is also FDA-approved for the prevention of CMV disease in recipients of organ transplants who are at risk for CMV diseases.
The listed CAS number is 175865-59-5.
The listed molecular formula is C14H23ClN6O5.
The listed molecular weight is 390.82 g/mol.
[2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate;hydrochloride.
The source lists Valcyte and Valcyt.